In this review:
- MOG-IgG positivity in MS
- Smoking at DMT initiation and disease outcomes in RRMS
- Headaches and migraines in MS
- Anti-CD20 discontinuation in stable MS patients aged >50
- Predictors of fatigue worsening in MS
- Early high-efficacy DMTs in MS
- GEMINI 1 and 2: tolebrutinib vs. teriflunomide in relapsing MS
- OCARINA II: updated efficacy and safety of subcutaneous ocrelizumab
- BLOOMS: B-cell tailored ocrelizumab dosing vs. standard interval dosing
- CCMR-Two: metformin plus clemastine for remyelination in RRMS
Please login below to download this issue (PDF)